Skip to content
‹ Back to IndustriesSciences

Chaperones Aren’t Just for the Prom: Key Step In Viral Replication Identified

Researchers at Children's Hospital of Pittsburgh have identified a key step in viral replication involving molecular chaperones, proteins that assist in the final stages of protein folding and virus assembly. This discovery advances scientific understanding of how viruses complete their construction inside host cells. The findings could open new avenues for antiviral therapies targeting this stage of the viral lifecycle.

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Sciences · ·
Share

Key takeaways

01

Molecular chaperones play a critical role in the final stages of viral protein folding and assembly.

02

Researchers at Children's Hospital of Pittsburgh identified this key step in viral replication.

03

Understanding this mechanism could inform the development of new antiviral treatments.

Free workspace

Turn your Sciences expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

Viruses are cellular parasites that reproduce themselves by hijacking the machinery of the cells they infect. We have significant knowledge regarding cell infection and virus reproduction of themselves within cells, but scarce is our understanding of the final stages of protein folding and virus construction. However, according to SciTechDaily, researchers at Children’s Hospital of Pittsburgh of UPMC and the University of Pittsburgh School of Medicine have published a report in Nature Microbiology revealing how the proteins of the common, normally harmless reovirus, are properly folded by the cell to produce the final viruses. 

The key is the common chaperonin protein complex, TriC. A given protein can potentially fold multiple ways, but the chaperonins help proteins in the cell to fold properly. In fact, it helps fold up to 10% of all the cell’s proteins, including important proteins such as cellular cytoskeleton proteins and cell cycle regulators. TriC is highly conserved across species, indicating its importance in proper protein folding and function. This conserved structure also suggests that TriC might be a common protein for viruses to use. 

The TriC helps the reovirus’s outer capsid proteins to fold such that they can assemble into virus particles capable of being released from the cell to infect new cells. Given the central role of TriC in properly folding reovirus proteins, scientists may find ways to inhibit the folding process. However, given the central importance of TriC as a chaperonin for 10% of the cell’s proteins, therapies must be conducted carefully to avoid damage to the cells themselves. 

Whether new therapies can be developed or not, understanding the roles of chaperonins like TriC is an important step to understanding the virus lifecycle. The more we understand about how viruses take over the cellular structure, the closer we are to understanding how to therapeutically fight these miniscule cellular parasites.

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

S
Sciences
B2B Weekly

The week in Sciences, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Sciences Insights

Crown Bioscience Appoints Guy Sheets as Senior Vice President, Commercial

Crown Bioscience appointed Guy Sheets as Senior Vice President, Commercial, bringing over 30 years of pharma and life sciences experience to lead the CRO's global commercial strategy. Sheets previously held senior commercial roles at QPS Holdings, CenExel, SGS Health Sciences, Lonza, and Thermo Fisher Scientific.

  • 01Guy Sheets brings 30+ years of commercial leadership across pharma, biotech, and life sciences, most recently as VP, Head of Global Business Development at QPS Holdings
  • 02Crown Bioscience operates 9 facilities across the US, Europe, and APAC with a portfolio of 2,800+ patient-derived xenograft models and 1,000+ tumor organoid models across 35 cancer indications
  • 03Sheets will lead Crown Bioscience’s global commercial strategy to drive growth, expand market presence, and strengthen client partnerships

Nov 3, 2026

Merck's €300 million Korean plant brings biologics supplies closer to Asia-Pacific drugmakers

Merck's €300 million Korean plant brings biologics supplies closer to Asia-Pacific drugmakers

Merck has invested more than €300 million in a new bioprocessing production center in Daejeon, South Korea. It is the largest life science investment Merck has made in the region to date. The 44,500-square-meter facility makes cell culture media, process liquids and sterile sampling products to support biologics manufacturing from development through commercial supply.

  • 01A single Asia-Pacific site now supplies both small custom pre-GMP media and commercial-scale media, so a regional biologics program could scale without switching to a source outside the region.
  • 02Daejeon supplies cell culture media, process liquids, ready-to-use cleaning-in-place solutions and sterile sampling products.
  • 03The useful supplier question has moved past whether Merck has an Asia-Pacific plant: ask which product lines ship from Daejeon and what batch traceability data customers can see.

Nov 3, 2026

IndexBox sees replacements driving a third of quantum cascade laser shipments by 2030

IndexBox sees replacements driving a third of quantum cascade laser shipments by 2030

IndexBox projects the quantum cascade laser market to grow 8% to 12% a year through 2035, linking the outlook to faster adoption of mid-infrared spectroscopy in process control, environmental monitoring and pharmaceutical QA. It says QCLs win on high spectral brightness and room-temperature operation in compact form factors, and that the installed base of analytical instruments is growing.

  • 01Roughly one in three quantum cascade lasers shipped in 2030 is projected to replace equipment already in service, so maintenance calendars will set a growing share of demand.
  • 02For a plant or QA lab running QCL-based analyzers, the useful question is which laser maker sits inside each instrument and whether a second source exists.
  • 03Analyzers bought on a three-to-five-year cycle in 2026 come due between 2029 and 2031. Those years will show whether the forecast replacement wave turns up in real orders.

Oct 26, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

S
Sciences

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512